Sanofi 6-K, filed May 9, 2022
Sanofi (SNY)
About this 6-K
Sanofi filed this 6-K on May 9, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2022
Commission File Number: 001-31368
SANOFI
(Translation of registrant’s name into English)
54, rue La Boétie, 75008 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ________
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ________
In May 2022, Sanofi published the press releases attached hereto as Exhibits 99.1 and 99.2 which are incorporated herein by reference.
Exhibit List
| Exhibit No. |
Description |
|||
| Exhibit 99.1 | Press release dated May 3, 2022: Annual General Meeting of May 3, 2022 | |||
| Exhibit 99.2 | Press release dated May 4, 2022: Foundation S: Sanofi’s new philanthropic spearhead | |||
2
Exhibit Index
| Exhibit No. |
Description |
|||
| Exhibit 99.1 | Press release dated May 3, 2022: Annual General Meeting of May 3, 2022 | |||
| Exhibit 99.2 | Press release dated May 4, 2022: Foundation S: Sanofi’s new philanthropic spearhead | |||
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Dated: May 9, 2022 |
SANOFI | |||||
| By | /s/ Alexandra Roger | |||||
| Name: Alexandra Roger | ||||||
| Title: Head of Securities Law and Capital Markets | ||||||
4
Exhibit 99.1
| Press Release |
|
Annual General Meeting of May 3, 2022
| • | Approval of the financial statements for the fiscal year 2021 |
| • | Distribution of a cash dividend of €3.33 per share and a dividend in kind of EUROAPI shares, at a ratio of one (1) EUROAPI share per twenty-three (23) Sanofi shares, with payment as of May 10, 2022 |
| • | Board composition: renewals and appointment of three new Independent Directors |
Paris, May 3, 2022. The Combined General Shareholders’ Meeting of Sanofi was held on May 3, 2022 at Paris Expo Porte de Versailles, under the chairmanship of Serge Weinberg. All resolutions submitted to the vote were adopted by the shareholders.
The General Meeting approved the individual Company and consolidated financial statements for the fiscal year 2021. The General Meeting decided on the distribution of an ordinary annual dividend of €3.33 per share and an additional dividend in kind in the form of an allocation of EUROAPI shares, at a ratio of one (1) EUROAPI share per twenty-three (23) Sanofi shares held. The payment of the dividend, including both the cash dividend and the dividend in kind, will be made on May 10, 2022.
The General Meeting also renewed Paul Hudson, Christophe Babule, Patrick Kron and Gilles Schnepp as Directors, and approved the appointment of Carole Ferrand, Emile Voest and Antoine Yver.
On the proposal of the Nomination, Governance and CSR Committee, Carole Ferrand has been appointed as member of the Audit Committee, Barbara Lavernos as member of the Nomination, Governance and CSR Committee, Wolfgang Laux as member of the Compensation Committee, and Emile Voest and Antoine Yver as members of the Scientific Committee.
Following the General Meeting, the Board of Directors is comprised of 16 members, of whom six are women and two are Directors representing employees. The Board of Directors remains for a large majority comprised of Independent Directors.
The voting results and the videocast of the Annual General Meeting are available on:
www.sanofi.com/AG2022
About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Nicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com
Investor Relations
Eva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.com
|
1/2 |
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2021. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
|
2/2 |
Exhibit 99.2
|
Press Release |
|
Foundation S: Sanofi’s new philanthropic spearhead
Paris, May 4, 2022. Sanofi today launches Foundation S – The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partnerships and collective action, Foundation S will focus on three critical areas: pediatric cancer, the health of communities most vulnerable to the effects of climate change and pollution, and access to lifesaving medicines and vaccines.
Serge Weinberg
Chairman of the Board of Directors, Sanofi and President, Foundation S
“As a global healthcare company, we must take part in tackling some of the challenges our society faces. We are proud of what the Sanofi Espoir Foundation has achieved this past decade and the legacy it leaves. The world changes at an incredible pace and numerous new systemic challenges emerge. Now is the right time to go one step further and Foundation S is the right structure, more focused, more agile, to better help vulnerable populations across the world. ”
Foundation S will incorporate as its cornerstone initiative the former Sanofi Espoir Foundation’s ‘My Child Matters’ program in pediatric cancer. Launched in 2005 to give every child an equal chance of survival, ‘My Child Matters’ provides financial support and expertise so that all children can access diagnosis and treatment. The program has helped more than 120,000 children, trained over 50,000 healthcare professionals and been credited with increasing survival outcomes. Additionally, Foundation S will fund awareness and research for pediatric cancer in various countries. Together, these initiatives support the World Health Organization (WHO) objective of achieving at least 60% survival for all children with cancer by 2030, saving an additional 1 million lives over the next decade.
Fighting for healthier futures requires addressing today’s challenges and anticipating growing crises. To that end, Foundation S will work to increase the health resilience of vulnerable populations most impacted by climate change and pollution. Foundation S will begin by collaborating with the international NGO Friendship, Bangladesh-based, focused on that nation’s hard-to-reach, climate-vulnerable islands of Gaibandha. There, Foundation S will help train healthcare workers, and fund satellite clinics and a floating hospital in a region outside mainstream healthcare services.
To better help vulnerable populations, Foundation S will leverage Sanofi’s longstanding emergency aid expertise and improve the connection between humanitarian and development financing. As in Ukraine, where the company has coordinated and accelerated donations of essential medicines and vaccines for patients and refugees, Foundation S will renew Sanofi’s emergency aid donations program and expand proactive support notably for displaced populations.
Paul Hudson
Chief Executive Officer, Sanofi and Board Member, Foundation S
“The launch of Foundation S is a new cornerstone of Sanofi’s commitment to society and a pivotal moment for the life of our company and our people. With Foundation S, we aim to weigh in and act on targeted areas where we know we can make a real difference for populations exposed to health difficulties.”
Foundation S will operate as a “think & do tank.” The ‘think-tank’ guides the development and implementation of Foundation S’s focus areas, convenes thought-provoking discussions on how to best address health challenges. The ‘do-tank’ is the operational arm that supports program implementation and monitors their impact on public health. Sanofi employees will be key to the success of the Foundation S and be empowered to support its programs and partners through volunteering and preceptorships: a period of practical experience to be gained.
|
1/2 |
Vanina Laurent-Ledru to head Foundation S – The Sanofi Collective
Vanina Laurent-Ledru will lead Foundation S. She was previously Head of Global Public Affairs for Sanofi Specialty Care. Before joining Sanofi, Laurent-Ledru worked on public health matters at the global vaccine alliance Gavi, and at other health companies.
Vanina Laurent-Ledru
Head of Foundation S
“We cannot change the world on our own – intelligence of the heart can only be collective. The launch of Foundation S is the culmination of joint ideas and forces. Collaborating with diverse and multicultural partners and our people, the Sanofi Collective combines our energy and expertise to deepen our impact for communities in need.”
This endowment fund allows Foundation S to open the opportunity for co-sponsorship of public initiatives and broader partnerships. Through its direct product donation programs and humanitarian efforts, and by working with partners and organizations around the world, Foundation S further strengthens Sanofi’s longstanding commitment to society.
About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
|
2/2 |